Australia's most trusted
source of pharma news
Saturday, 02 August 2025
Posted 1 August 2025 AM
Antengene has signed an exclusive agreement with Arrotex to be the exclusive distribution and commercialisation partner in Australia for blood cancer drug Xpovio.
It's the latest step in a move by Arrotex to expand into branded and innovative medicines, and comes after the recent formation of a haematology and oncology focused specialty sales team by the company.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.